Stock Market & Financial Investment News

News Breaks January 28, 2013 08:43 EDT ACT, AMGN Activis Investor Day increases confidence, says Susquehanna Susquehanna came away from Activis' (ATV) Investor Day with increased confidence citing guidance for double digit organic growth, the collaboration for biosimilars with Amgen (AMGN), and its commitment to growing its branded business longer-term. Shares are Positive rated. News For ACT;AMGN From The Last 14 Days Check below for free stories on ACT;AMGN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. 1 | 2 | all recent news | >> June 19, 2013 08:04 EDT ACT Actavis and Kissei file patent infringement lawsuits against Sandoz and Hetero Subscribe for More Information 07:51 EDT ACT EC fines Ranbaxy, others for blocking cheaper drugs, Economic Times reports Subscribe for More Information June 18, 2013 19:07 EDT AMGN On The Fly: After Hours Movers Subscribe for More Information 17:25 EDT AMGN Amgen reports 7.58% stake in Cytokinetics Subscribe for More Information June 17, 2013 13:20 EDT ACT Supreme Court rules generic drug makers can be sued over 'pay to delay' Subscribe for More Information 11:54 EDT ACT Supreme Court ruling a modest negative for generics, says Leerink Subscribe for More Information 11:49 EDT ACT U.S. Supreme Court reverses U.S. Court of Appeals decision in FTC vs. Actavis Subscribe for More Information 07:25 EDT ACT Leerink to host a conference Subscribe for More Information June 16, 2013 11:44 EDT AMGN Amgen still looks attractive, Barron's says Subscribe for More Information June 13, 2013 11:06 EDT AMGN FDA approves Xgeva to treat giant cell tumor of the bone Subscribe for More Information 11:04 EDT AMGN FDA approves Xgeva to treat giant cell tumor of the bone Subscribe for More Information 07:32 EDT AMGN European League Against Rheumatism to host annual meeting Subscribe for More Information June 12, 2013 09:13 EDT AMGN Amgen, AstraZeneca to advance brodalumab into Phase 3 studies Subscribe for More Information 09:04 EDT AMGN Amgen announces positive top-line results of Phase 3 trebananib Subscribe for More Information 07:39 EDT AMGN Amgen, Cytokinetics announce expansion of license for omecamtiv mecarbil Subscribe for More Information 07:08 EDT ACT Drugstores ready access changes to Plan B pill, WSJ reports Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, reports the Wall Street Journal.Reference Link 06:53 EDT ACT Columbia Laboratories announces class action lawsuit against company dismissed Subscribe for More Information 06:05 EDT ACT On the Fly: Periodicals Wrap-Up WALL STREET JOURNAL: The tectonic plates of the world economy are shifting, moving the yield on the 10-year Treasury to the highest level in more than a year and shaking financial markets. Now, some constants are being questioned in markets, triggering paroxysms in stocks, bonds, commodities and the currencies of emerging markets, the Wall Street Journal reports...Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, the Wall Street Journal reports...REUTERS: If currency turbulence in emerging markets becomes a full-scale investor flight, the Fed may have a new headache in deciding when to slow its dollar printing policy. The link between U.S. monetary policy and currency runs on the other side of the world could be tighter than many assume, Reuters reports...Toyota Motor (TM) said it’s unlikely to recapture its peak market share it held four years ago in the U.S. (GM, F), its biggest market, the latest sign the carmaker is shifting to improving quality from aggressively expanding sales, Reuters reports...BLOOMBERG: Exchange executives (NYX, NDAQ), long shielded from legal scrutiny in the U.S., have been put on notice that may be changing after federal regulators fined CBOE Holdings (CBOE) $6M for unprecedented lapses in supervision, Bloomberg reports...Borealis Infrastructure Management and its Kuwaiti-British partners abandoned their $8.3B bid for the U.K. water utility Severn Trent (SVTRY) as the offer deadline expired, Bloomberg reports. June 11, 2013 17:59 EDT ACT Actavis, Medicines360 announce partnership Medicines360, a non-profit pharmaceutical company, and Actavis, announced a partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S. public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device, or IUD. Medicines360 retains rights to market the product in the U.S. public sector, including family planning clinics that provide services to low-income women. LNG20, originally developed by Uteron Pharma S.P.R.L. in Belgium, is designed to initially deliver 20 mcg of levonorgestrel per day for the indication of long term contraception, and is currently in Phase III clinical trials in the United States. Pending FDA approval, the LNG20 IUD could be launched in the U.S. as early as 2014. 10:14 EDT ACT Actavis acquires U.S. commercial rights for LNG20 IUD Medicines360, a non-profit pharmaceutical company, and Actavis announced a partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S. public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device. Medicines360 retains rights to market the product in the U.S. public sector, including family planning clinics that provide services to low-income women. LNG20 is currently in Phase III clinical trials in the United States. Pending U.S. Food and Drug Administration approval, the LNG20 IUD could be launched in the U.S. as early as 2014, the companies said. 1 | 2 | all recent news | >> Sign up for a free trial to see the rest of the stories you've been missing.